Neurotoxic events associated with BCR-ABL1 tyrosine kinase inhibitors: a case series

MLA

Naval Daver, et al. “Neurotoxic Events Associated with BCR-ABL1 Tyrosine Kinase Inhibitors: A Case Series.” Leukemia & Lymphoma, vol. 60, June 2019, pp. 3292–95. EBSCOhost, https://doi.org/10.1080/10428194.2019.1633635.

APA

Naval Daver, Carlos Kamiya-Matsuoka, Hind Rafei, Rohtesh S. Mehta, Tapan M. Kadia, Elias Jabbour, Kiran Naqvi, Hagop M. Kantarjian, Jorge E. Cortes, Marina Konopleva, & Kaylyn D Sinicrope. (2019). Neurotoxic events associated with BCR-ABL1 tyrosine kinase inhibitors: a case series. Leukemia & Lymphoma, 60, 3292–3295. https://doi.org/10.1080/10428194.2019.1633635

Chicago

Naval Daver, Carlos Kamiya-Matsuoka, Hind Rafei, Rohtesh S. Mehta, Tapan M. Kadia, Elias Jabbour, Kiran Naqvi, et al. 2019. “Neurotoxic Events Associated with BCR-ABL1 Tyrosine Kinase Inhibitors: A Case Series.” Leukemia & Lymphoma 60 (June): 3292–95. doi:10.1080/10428194.2019.1633635.